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INTRODUCTION 
Pain in the orofacial region, especially odontalgia, is all too common (Riley and 
Gilbert 2001).  A 1993 survey of a United States population found that 12.2% of adults 
experienced odontalgia in the past 6 months (Lipton et al. 1993).  Approximately one-
third of all dental emergencies are endodontic emergencies, and as many as 90% of 
dental emergencies involving pain are pulpal or periapical in origin (Rossman et al. 
2006).  Management of the dental emergency can be systematically approached using a 
triad of key points: Diagnosis, definitive treatment (removal of etiology) with proper 
local anesthesia, and assignment of a drug regimen that contributes analgesic and anti-
inflammatory mechanisms (Hargreaves and Keiser 2004).  
Pain produces an incentive for the patient to seek dental care.  This pre-operative 
pain can often persist following initiation and/or completion of root canal treatment.  
More than 40% of patients who underwent chemomechanical root canal preparation 
reported post-operative pain in the first 24 hours following treatment (Georgopoulou et 
al. 1986).  Even without pain before root canal treatment, an incidence of slight post-
operative pain in 28.8%, or moderate to severe post-operative pain in 15.7% following 
pulpal debridement occurs (Harrison et al. 1983a).  A number of studies, however, have 
demonstrated that the incidence of post-operative pain is considerably higher when 
patients report pre-treatment pain (O'Keefe 1976; Torabinejad et al. 1988; Walton and 
Fouad 1992; Mattscheck et al. 2001), and that post-operative pain is most severe within 
the first 24 hours following treatment (Harrison et al. 1983a; Torabinejad et al. 1994b; 
Mattscheck, et al. 2001). 
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Clinical trials have shown that the incidence of moderate or severe post-operative 
pain following endodontic therapy is strongly correlated with the initial cleaning and 
shaping procedure rather than with final obturation of the root canal system (Taintor and 
Ross 1978; Harrison et al. 1983b; Torabinejad et al. 1994a; Walton and Fouad 1992).  
Pain from a surgical incision or tissue manipulation may occur immediately, but this 
gives way to inflammatory pain following inflammatory cell recruitment to the injured 
area over the course of several hours (Gordon et al. 2010). 
A higher incidence of post-operative pain may occur in teeth with necrotic versus 
vital pulpal status.  Walton and Fouad (1992) observed a positive correlation with severe 
post-operative symptoms in patients having a pre-treatment diagnosis of pulpal necrosis 
and painful apical pathosis. 
Previous studies have also suggested that sex differences may play a role in pain 
perception.  In an oral surgery model, it was reported that females presented for treatment 
with higher baseline pain levels than men (Averbuch and Katzper 2000).  In a study by 
Ng et al. evaluating the incidence of post-operative endodontic pain, females were 
determined to be a significant prognostic factor (Ng et al. 2004).  Other factors that were 
prognostic determinants of post-operative pain included molar teeth, apical lesions less 
than 3 mm in diameter, and single-visit treatments.  A study by Morin et al. observed that 
females find post-surgical pain more intense than males, but males are more disturbed 
than females by low levels of pain that lasts several days (Morin et al. 2000).  
To minimize post-operative pain following endodontic treatment opioid 
analgesics are frequently prescribed, and while effective, can be associated with side 
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effects such as drowsiness, nausea and vomiting, constipation, and with long term use, 
tolerance and dependence.  Even non-steroidal anti-inflammatory agents have adverse 
effects such as cardiovascular and peptic ulcers, and cannot be used with all patients.  
The additional use of long-acting local anesthetics has shown the ability to provide an 
increased duration of post-treatment analgesia beyond the period of anesthesia (Moore 
and Dunsky 1983; Dunsky and Moore 1984; Crout et al. 1990; Parirokh et al. 2012; Al-
Kahtani 2014).  Long acting local anesthetics may also reduce analgesic use and 
analgesic-related adverse events.  Since endodontic treatment by itself often provides 
substantial pain relief by 24 hours, the use of long-acting local anesthetics represent a 
logical means for inclusion in the management plan for post-operative pain (Keiser and 
Hargreaves 2002). 
 The purpose of this clinical trial was to compare post-operative pain levels 
following the first stage of two-visit emergency endodontic treatment in patients with 
either an intermediate-acting local anesthetic (2% lidocaine with 1:100,000 epinephrine) 
or a long-acting local anesthetic (0.5% bupivacaine with 1:200,000 epinephrine). 
 
HYPOTHESIS 
Patients receiving a long-acting local anesthetic (bupivacaine) will report lower 
postoperative pain levels following emergency endodontic treatment when compared to 
patients who received emergency endodontic treatment with an intermediate-acting local 
anesthetic (lidocaine), without regard to post-operative analgesics given. 
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LITERATURE REVIEW 
Tissue Damage and Pain 
Clinical pain can be categorized as inflammatory or neuropathic pain.  
Inflammatory pain generally refers to pain associated with peripheral tissue damage, 
where neuropathic pain is associated with damage to the nervous system (Woolf and 
Chong 1993). The most common etiology of pulpal inflammation is microbial infection, 
while the second most common cause of pulpal inflammation is traumatic injury 
(Hargreaves and Hutter 2002). 
Pain occurs due to direct activation of nociceptive fibers, often by inflammatory 
mediators.  Pain may be expanded due to peripheral or central hypersensitivity caused by 
posttranslational and transcriptional changes in peripheral nociceptor terminals and dorsal 
horn neurons (Woolf and Costigan 1999).  Sources of pain may be related to a state 
where the intensity required to initiate a painful response is reduced to a threshold such 
that a normally innocuous stimulus will result in pain, also known as allodynia.  An 
exaggerated response to a stimulus that would normally be noxious is known as 
hyperalgesia (Treede et al. 1992; Woolf 1989). 
The sensory innervation of the dental pulp includes numerous branches that stem 
from afferrent myelinated A fibers or unmyelinated C fibers (Byers et al. 2012)  
Innocuous peripheral mechanical stimuli are generally transmitted by large A-beta 
primary sensory fibers, while smaller A-delta and C fibers are responsible for 
transmitting noxious stimuli (Treede et al. 1992; Willis and Coggeshall 2004). 
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Odontogenic pain generally occurs following a noxious physical stimulus or an 
influx of inflammatory mediators that activate terminal receptors on afferent C and A-
delta fibers (Willis 1985; Woolf and Costigan 1999; Hargreaves and Milam 2001).  Slow-
conducting, unmyelinated C-fibers comprise more than half of the nerve fibers in human 
dental pulp, and they are likely responsible for pain that is poorly localized with dull and 
lingering qualities. Most of the myelinated axons entering the root apex area are fast-
conducting A-delta fibers, likely responsible for sharp and brief localized pain (Nair 
1995). 
Some of the structural features associated with the dental pulp certainly make 
pulpal pain unique, however, the peripheral mechanisms associated with odontogenic 
pain share similarities with peripheral pain in the rest of the body (Henry and Hargreaves 
2007).  The dorsal horn is most often discussed when the central nervous system (CNS) is 
referred to, however, for orofacial pain, the trigeminal nucleus within the pontine brain 
stem is the correlate of the dorsal horn.  Peripheral afferent impulses travel through the 
trigeminal ganglion and enter the CNS through the pons, descending along the trigeminal 
tract in order to reach the trigeminal nucleus where they synapse with second-order 
neurons (Merrill 2007). 
Intrinsic neurons are excited primarily within the superficial lamina of the 
trigeminal nucleus caudalis by the release of glutamate, an excitatory amino acid, along 
with neuropeptides (De Biasi and Rustioni 1988). Peptides play an important role in the 
activation of nociceptors in the spinal system, but their role has also been identified in the 
dental pulp, some of which include Substance P (SP) (Olgart et al. 1977), bradykinin 
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(Goodis et al. 2000), neurokinin A (NKA), vasoactive intestinal peptide (VIP), 
neuropeptide Y (NPY), calcitonin gene related peptide (CGRP) (Uddman et al. 1986), 
and nerve growth factor (NGF) (Wheeler et al. 1998). Extracellular levels of substance P 
are positively correlated with inflammation and pain (Byers and Taylor 1993; Traub 
1996), and an eight-fold increase in substance P concentrations have been demonstrated 
in symptomatic pulps diagnosed with irreversible pulpitis (Bowles et al. 2003).  Lepinski 
et al. found an almost 13-fold increase in bradykinin levels in inflamed pulps (Lepinski et 
al. 2000). 
While many inflammatory mediators activate nociceptors, some produce 
persistent effects or potentiate the effects of other inflammatory mediators.  Nerve growth 
factor concentrations in the inflamed dental pulp can increase by a factor of 8 times 
compared with the uninflamed pulp (Byers et al. 1994; Wheeler et al. 1998).  Injections 
of nerve growth factor in healthy humans have been shown to evoke persistent pain and 
allodynia for weeks (Petty et al. 1994; Byers and Narhi 1999). Peripheral afferent fibers 
respond to nerve growth factor by increasing synthesis of CGRP and substance P, and by 
sprouting terminal fibers into the inflamed tissue, which may contribute to increased 
sensitivity in pulpal or periradicular tissues (Byers et al. 1990; Byers 1994; Byers and 
Narhi 1999). 
Prostaglandins contribute to the development of the cardinal signs of acute 
inflammation, and play a key role in the generation of the inflammatory response 
(Ricciotti and FitzGerald 2011).  Prostaglandin E2 (PGE2) has been demonstrated to 
significantly increase the stimulatory effect of bradykinin in an ex vivo bovine dental pulp 
  7 
model (Goodis et al. 2000).  A significant increase in the production of PGE2 has been 
detected in inflamed periradicular tissues, especially when pain and/or swelling is present 
(McNicholas et al. 1991). 
A variety of types of receptors and ion channels associated with second-order 
neurons play a role in modulatory circuits that can facilitate or inhibit pain transmission. 
If a peripheral inflammatory process produces intense afferent activity and neuronal 
damage, a central process can begin, leading to increased sensitization, lower response 
threshold, ectopic discharge, and pain signaling from fibers that typically carry innocuous 
stimuli, for example, A-beta fibers(Merrill 2007). 
 
Management of Endodontic Pain 
Management of endodontic pain should focus on the removal of peripheral 
mechanisms that cause hyperalgesia and allodynia.  This is generally achieved through 
removal and reduction of bacterial and immunologic factors (Hargreaves et al. 1994; 
Keiser and Byrne 2011).  Endodontic treatments such as pulpotomy or pulpectomy have 
demonstrated substantial reduction in patient-reported pain compared with pretreatment 
pain levels (Hasselgren and Reit 1989; Hargreaves 1997; Doroschak et al. 1999; 
McDougal et al. 2004). Frequently, however, the addition of a pharmacological approach 
is required to reduce continued nociceptor input using local anesthetics or non-steroidal 
anti-inflammatory drugs (NSAIDs), and suppression of central hyperalgesia may be 
achieved with drugs such as NSAIDs or opioids (Keiser and Byrne 2011). 
 
  8 
Local Anesthetics 
The use of effective local anesthesia is critical in endodontics, as treatment cannot 
be performed without adequate pain control.  The use of local anesthesia was introduced 
in 1884 when Karl Koller used cocaine as an anesthetic during ophthalmic surgery 
(Ruetsch et al. 2001).  Following a prominent history of toxicity, addiction, and 
sometimes fatal effects associated with the use of cocaine as a local anesthetic, Alfred 
Einhorn introduced procaine in 1904 as a safer, less addicting alternative.  It was soon 
learned, however, that the vasodilatory effects of procaine caused a profound drop in 
blood pressure, allowing the anesthetic to travel widely from the site of injection.  This 
was overcome by the combination of procaine with the α-adrenergic vasoconstrictive 
properties of epinephrine (Ring 2007). 
The chemical structure of early local anesthetics such as cocaine and procaine 
contain an ester linkage, which is responsible for a high incidence of allergic reactions.  
The most common forms of local anesthetics used in dentistry today contain an amide 
linkage, which carries a far lower risk for allergenicity.  Lidocaine was introduced in the 
1950’s and has become the prototypic dental anesthetic in North America due to its 
excellent efficacy and safety (Moore and Hersh 2010).  In 1963 bupivacaine was 
introduced as an amide local anesthetic possessing a long duration of action, primarily 
due to its lipid solubility and protein-binding characteristics (Covino and Vassallo 1976). 
Local anesthetics can generally be categorized into three types based on their 
duration of action: short-acting (approximately 30 mins of pulpal anesthesia), 
intermediate-acting (approximately 60 mins of pulpal anesthesia), and long-acting (over 
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90 minutes of pulpal anesthesia).  The duration of anesthesia achieved clinically with 
each local anesthetic depends, however, on the route of administration (i.e. block versus 
infiltration) (Reader et al. 2011). 
Bupivacaine (with 1:200,000 epinephrine), for example, is considered a long-
acting local anesthetic, and studies have shown an average of 4 hours of pulpal anesthesia 
following inferior alveolar nerve block (Fernandez et al. 2005).  Using the same 
anesthetic as infiltration for anterior teeth, it demonstrated a shorter duration of action 
than lidocaine (with 1:100,000 epinephrine), which is generally classified as having an 
intermediate duration of action (Danielsson et al. 1985; Gross et al. 2007). 
Another factor affecting the duration of a local anesthetic is the addition (or 
absence) of a vasoconstrictor. This addition delays the systemic absorption of the 
anesthetic solution, reducing the risk for toxicity, but also prolonging the local duration 
of anesthesia.  Epinephrine is the agent most commonly used for this purpose, due to its 
alpha-1 agonistic action (Becker and Reed 2006).  Solutions containing 1:100,000 
epinephrine are popular, however, research has shown that concentrations higher than 
1:200,000 epinephrine do not provide faster onset or greater duration when used for 
inferior alveolar blocks (Dagher et al. 1997; Tofoli et al. 2003). 
Clinically relevant local anesthetics used in dentistry are comprised of an amine 
on one end with an ester or amide intermediate chain linked to a lipophilic aromatic ring 
on the other end.  The aromatic ring improves the lipid solubility of the compound.  The 
more lipid soluble a molecule is, the more readily it can diffuse through nerve sheaths 
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and neural membranes.  Lipid solubility correlates with the potency of the local 
anesthetic (Becker and Reed 2006).  
 
 
 
 Fig. 1a Chemical Structure of Lidocaine         Fig. 1b Chemical Structure of Bupivacaine 
 
The terminal amine may exist in either a charged (quaternary) or an uncharged 
(tertiary) form. While the aromatic ring determines the degree of lipid solubility, the 
terminal amine acts as a switch that alters the molecule to exist in either a water-soluble 
(charged) conformation or a lipid-soluble (uncharged) conformation.  Prior to injection, 
the anesthetic exists in the quaternary, water-soluble form. This charged conformation of 
the molecule is unable to penetrate the neuron, and must first be converted to the 
uncharged tertiary form.  The onset of local anesthesia is dependent on the proportion of 
molecules that convert to the uncharged form when exposed to physiologic pH.  The pKa, 
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or ionization constant refers to the pH at which fifty percent of the molecules exist in the 
charged, water-soluble form and fifty percent in the uncharged, lipid-soluble form. Once 
the lipid soluble form exists, it can diffuse through the neural sheath and neural 
membranes, where it targets ion channels. 
Voltage-gated ion channels, including potassium (K+), calcium (Ca2+), and 
sodium (Na+) channels, are transmembrane, pore-forming proteins that allow the 
selective passage of certain ions in a voltage-dependent manner.  The activation of Na+ 
channels is critical in the initiation and propagation of action potentials (nerve impulse).  
When a transient generator potential is created by the activity of other ion channels, the 
opening of the voltage-gated Na+ occurs.  As Na+ ions enter the axon, depolarization 
occurs.  If a depolarizing threshold is reached, the result is initiation of an action 
potential.  Therefore, drugs such as local anesthetics that block sodium channels (e.g. 
lidocaine, mepivacaine, bupivacaine, articaine) play a critical role in dental therapeutics 
(Henry and Hargreaves 2007). 
A dramatic increase in the expression of voltage-gated sodium channels has been 
demonstrated in the inflamed dental pulp, which can lead to a significant impact on the 
transmission of action potentials from the pulp and periradicular regions (Henry et al. 
2009; Luo et al. 2008; Wells et al. 2007). 
Sodium channels can be classified according to their susceptibility to tetrodotoxin 
(TTX), where they may be considered either TTX-sensitive or TTX-resistant (Arbuckle 
and Docherty 1995).  A majority of TTX-resistant channels are found primarily on 
nociceptors (Wells et al. 2007).  Furthermore, these afferent fibers are sensitized by 
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prostaglandins (Gold et al. 1996) and it has been suggested that TTX-resistant channels 
are relatively resistant to local anesthetics (Roy and Narahashi 1992; Scholz et al. 1998). 
In a study comparing the ability of lidocaine and bupivacaine to reduce firing 
frequency in both TTX-sensitive and TTX-resistant sodium channels, the two anesthetic 
solutions were equally effective for TTX-sensitive channels, however, bupivacaine 
showed greater efficacy in TTX-resistant channels (Scholz et al. 1998).  
Local anesthetics may contribute to the treatment of odontogenic pain through 
additional mechanisms.  G protein-coupled receptors (GPCRs) are the target of many 
classes of drugs (e.g. opioids, catecholamines), but local anesthetics have also shown the 
ability to modulate certain classes of these receptors (Reader et al. 2011).  The G-alpha-q 
class of GPCRs includes receptors activated by bradykinin.  Studies have suggested that 
local anesthetics can inhibit these receptors, thereby blocking the actions of a major 
hyperalgesic agent (Hollmann et al. 2004). 
Studies have demonstrated analgesia that lasts well beyond the period of 
anesthesia when long-acting local anesthetics are used (Moore and Dunsky 1983; Dunsky 
and Moore 1984; Crout et al. 1990; Keiser and Hargreaves 2002), and prolonged 
alteration in GPCR function might help explain this phenomenon(Reader et al. 2011).  In 
a periodontal surgery model, it has been observed that the administration of a block 
injection with a long-acting local anesthetic such as bupivacaine can provide analgesia 
for up to 10 hours, and that reports of perceived pain may be reduced at periods as long 
as 48 hours after administration (Crout et al. 1990).  In more recent clinical trials, patients 
with irreversible pulpitis who received bupivacaine prior to endododontic treatment 
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reported significantly lower levels of pain after 12 hours and used fewer analgesics when 
compared to patients receiving lidocaine (Parirokh et al. 2012; Al-Kahtani 2014).  
While long-acting local anesthetics have demonstrated prolonged 
anesthesia/analgesia when administered by mandibular nerve block, the same may not be 
true for maxillary infiltration.  When the use of long-acting local anesthetic infiltration in 
maxillary endodontic surgery was examined, soft tissue anesthesia lasted significantly 
longer, however, pain experience and analgesic intake did not differ from that of patients 
receiving lidocaine (Meechan and Blair 1993).  In a study comparing the duration of 
pulpal anesthesia achieved with bupivacaine and lidocaine when delivered by maxillary 
infiltration, it was concluded that bupivacaine did not fulfill the concept of a long-acting 
local anesthetic  (Gross et al. 2007). 
Research has suggested that central sensitization can be reduced or inhibited by 
the administration of a long-acting local anesthetic before and/or immediately after 
surgery (Gordon et al. 1997; Kaurich et al. 1997; Gordon et al. 2002).  By blocking the 
activation of nociceptors, not only is anesthesia provided but, by reducing the potential 
for central sensitization, analgesia is provided as well (Keiser and Hargreaves 2002). 
Modification of the dosage of a local anesthetic may be required due to certain 
systemic diseases or disorders.  Patients with severe cardiac conditions, including 
unstable angina pectoris, recent myocardial infarction or stroke (within the past 6 
months), severe hypertension, or uncontrolled congestive heart failure, should not receive 
a local anesthetic containing a vasoconstrictor, and should consult with a physician 
before treatment (Naftalin and Yagiela 2002). 
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Even relatively small amount of epinephrine, when delivered by nerve block or 
intraosseous injection, have shown the ability to cause increases in heart rate (Goldstein 
et al. 1982; Replogle et al. 1999), systolic blood pressure, and cardiac output (Goldstein 
et al. 1982). 
Inadvertent intravenous injection or large doses of local anesthetic can lead to 
acute toxicity and CNS depression (Finder and Moore 2002; Naftalin and Yagiela 2002).  
Although rare, systemic effects from local anesthesia may include tremors, seizures, 
hypotension, and respiratory arrest (Finder and Moore 2002; Dernedde et al. 2004).  To 
minimize the risk for adverse effects, the clinician must always aspirate before delivering 
an injection, and should use dosages within accepted guidelines (Reader et al. 2011). 
Local anesthetics have the potential to interact with certain medications, so it is 
critical to perform a thorough review of each patient’s medical history(Naftalin and 
Yagiela 2002).  Potential drug-drug interactions occur primarily with the vasoconstrictors 
in local anesthetic formulations, and the use of anesthetic formulations without 
vasoconstrictors may be indicated (Reader et al. 2011). 
 
Analgesics 
Non-narcotic Analgesics 
Non-narcotic analgesics are one major class of drugs for the management of 
endodontic pain both preoperatively and postoperatively. The primary approach with 
these drugs is to block inflammatory mediators that sensitize or activate pulpal 
nociceptors.  This category includes NSAIDs as well as acetaminophen (Khan and 
  15 
Hargreaves 2012).  These drugs are classically believed to produce analgesic effects 
through peripheral mechanisms, however, the CNS is now thought to be an additional site 
of action (Malmberg and Yaksh 1992; Svensson and Yaksh 2002).  It has been shown 
that NSAIDs prevent the production of prostaglandins by inhibition of the enzyme 
cyclooxygenase (COX) (Vane 1971; Smith and Willis 1971). 
Prolonged pain following a surgical procedure may develop as result of 
sensitization, beginning with an increased expression of proinflammatory cytokines and 
COX enzymes, leading to an increased production of prostanoids 2 to 4 hours post-
operatively (Woolf and Chong 1993).  For many years COX was thought to be a single 
constitutive enzyme present in most tissues, however, COX activity has been found to be 
increased by certain inflammatory states and can be induced by inflammatory cytokines 
(Raz et al. 1988; Fu et al. 1990; Masferrer et al. 1992; Sano et al. 1992).  Further research 
has suggested the existence of two isoforms of COX, a constitutive enzyme present in 
tissues such as the stomach and kidneys (COX-1), and another form of COX associated 
with inflammation (COX-2) (Kujubu et al. 1991; Sirois and Richards 1992; Xie et al. 
1991). 
Although traditional commercially available NSAIDs are effective, 
gastrointestinal and renal toxicity limits their use, due to non-selective inhibition of pro-
inflammatory prostaglandins produced by COX-2, as well as physiologically important 
prostaglandins produced by COX-1 (Seibert et al. 1994).  In more recent years, selective 
COX-2 inhibitors were introduced, showing the potential for both analgesic and anti-
inflammatory benefits with reduced gastrointestinal irritation (Dionne 1999; Khan and 
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Dionne 2002).  Major concerns over the safety of selective COX-2 inhibitors have arisen 
following the recognition of prothrombic adverse effects associated with these drugs.  
The demonstration of increased risk for prothrombic events following long-term use of 
rofecoxib, a selective COX-2 inhibitor, led to withdrawl of the drug from U.S. market in 
2004 (FDA 2004). 
Ibuprofen is often considered the prototype of NSAIDs, and its efficacy and 
safety profile have been well documented (Dionne et al. 1983).  In a post-extraction oral 
surgery model, 400 mg ibuprofen demonstrated superior efficacy over 25 mg ketoprofen, 
1000 mg acetaminophen, or placebo (Olson et al. 2001). 
Many NSAIDs have shown greater efficacy when compared with traditional 
acetaminophen or opiod combinations such as acetaminophen with codeine (Dionne 
1986; Troullos et al. 1986).  In conjunction with endodontic treatment such as 
pulpectomy or pulpotomy, NSAID therapy alone has been shown to be sufficient in many 
cases, however, when additional analgesia is needed, opiods or acetaminophen may serve 
as an important adjunct (Hargreaves and Keiser 2004). 
Studies have proposed that COX-3, a variant of the COX-1 enzyme is the primary 
site of action of acetaminophen (Chandrasekharan et al. 2002; Schwab et al. 2003; Kis et 
al. 2004), but more recent studies have indicated that the action of acetaminophen is more 
likely through the effects of an active metabolite on CNS cannabinoid receptors 
(Anderson 2008).  Acetaminophen can be used for pain relief alone or in combination 
with NSAIDs or narcotics.  In a clinical trial examining post operative pain following 
pulpectomy, the combination of 1000 mg acetaminophen with 600 mg ibuprofen 
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demonstrated significantly greater pain relief versus 600 mg ibuprofen or placebo over an 
eight hour observation period (Menhinick et al. 2004). 
Acetaminophen is considered safe when taken at normal doses but may cause 
liver toxicity at higher doses, and it has become the most common cause of acute liver 
failure (Larson et al. 2005).  A majority of a normal dose of acetaminophen is conjugated 
in the liver, forming inactive metabolites.  A small portion is metabolized to form N-
acetyl-p-benzoquinone imine (NAPQI).  NAPQI is highly toxic, but is typically 
converted by glutathione into nontoxic compounds.  If a large dose of acetaminophen 
saturates the main route of metabolism, increased amounts of NAPQI are formed. If 
glutathione becomes depleted NAPQI can accumulate, leading to liver injury (Keiser and 
Byrne 2011). 
 
Opioid Analgesics 
Opioids are effective analgesics for moderate to severe pain, and they are often 
used in dentistry in combination with acetaminophen or other NSAIDs.  Most clinically 
available opioids activate mu opioid receptors in the brain, inhibiting the transmission of 
signals to higher brain regions.  Opioid use is generally limited by their side effects, 
which can include nausea, emesis, dizziness, drowsiness, constipation, and respiratory 
depression.  Oderda et al. analyzed data from almost 61,000 patients given opioid 
analgesics for post surgical analgesia, and found an incidence of adverse drug events that 
were at least moderate in severity of approximately 3% (Oderda et al. 2003). 
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Pre-emptive Analgesia 
Pre-operative administration of anti-inflammatory and analgesic drugs have been 
examined with the rationale that they may reduce the input from peripheral nociceptors, 
thereby blocking the development of hyperalgesia. A significant decrease in 
postoperative pain levels has been suggested with preoperative administration of NSAIDs 
(Dionne 1986; Jackson et al. 1989) or acetaminophen (Moore et al. 1986).  More recent 
research, however, has indicated that pretreatment with analgesics may not significantly 
reduce postoperative pain below that achieved with endodontic treatment alone (Attar et 
al. 2008), unless the analgesic regimen is continued beyond the initial dose. 
 
Pain Measurement 
Pain is an unpleasant sensory and emotional experience. It is a phenomenon 
consisting of multiple dimensions having sensory, cognitive, and motivational 
components, and it can be very challenging to objectively assess all the attributes of pain 
(Kumar et al. 2002). In order to appreciate the subjective nature of the pain experience 
from one patient to the next, subjective methods of measurement such as the Visual 
Analog Scale (VAS), Heft Parker Scale, or Categorical Scale may be useful. 
The Categorical Scale consists of four points ranging from “no pain” to “severe 
pain,” and asks the patient to choose the point that best represents their current level of 
pain.  Although simple, it has been demonstrated that the Categorical Scale is a reliable 
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and reproducible method for measurement of pain in clinical trials (Averbuch and 
Katzper 2004). 
The VAS is a widely used method for measuring the intensity of pain following 
surgery. This scale asks patients to place a mark on a 100 mm horizontal line representing 
their current level of pain, where 0 mm represents no pain and 100 mm represents a 
maximum level of pain.  Following a critical review of some of the available objective 
and subjective methods for pain measurement, the VAS was established as methodically 
sound, conceptually simple, easy to administer, and unobtrusive to the patient (Coll et al. 
2004).  Further research has demonstrated that the VAS is reproducible and unaffected by 
gender (Goddard et al. 2004). 
The Heft Parker Scale was developed as a way to combine categorical descriptive 
words with a VAS-type horizontal line. This scale consists of a 170 mm horizontal line 
with 8 irregularly spaced descriptive words.  The patient is asked to place a mark on the 
horizontal line that represents their current level of pain. Heft and Parker designed this 
scale with the intention that patients would make categorical judgments based on their 
understanding of the words and that the categorical ratings are not simply an ordinal 
index (Heft and Parker 1984).  
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MATERIALS AND METHODS 
The protocol for this study was approved by the Institutional Review Board (IRB) 
at the University of Minnesota and can be identified by IRB code number 1311M45821.  
Patients presenting to the University of Minnesota School of Dentistry with pain 
diagnosed as endodontic in origin were screened for inclusion into the study. 
Patients presenting to the Endodontic clinic were pre-screened by being asked to 
score their current pain level using a Verbal Numeric Rating Scale (VNRS) (Holdgate et 
al. 2003). The VRNS requires a verbal response by the patient ranging from zero to ten 
with zero indicating ‘no pain’ and ten indicating ‘worst pain imaginable.’  Patients 
reporting moderate or severe tooth pain (>3 out of 10 on the VNRS) were invited to 
participate in a research study evaluating post-endodontic pain.  If the patient consented 
to be included in the study and met the following inclusion criteria with none of the 
exclusion criteria, they were eligible to participate in the study. 
 
Inclusion Criteria 
Potential subjects for this study included healthy adults between 18 and 65 years 
of age, with an ASA class I or II ranking based on medical history.  The patients were 
considered candidates if they presented for endodontic treatment with a pre-treatment 
VNRS score greater than or equal to 3 out of 10.  All patients exhibited symptoms 
associated with irreversible pulpitis, pulpal necrosis, previously initiated treatment, or 
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previous endodontic treatment.  Patients exhibited an apical diagnosis of normal apical 
tissues, symptomatic apical periodontitis, asymptomatic apical periodontitis, acute apical 
abscess, or chronic apical abscess.  Finally, all patients were required to have the ability 
to read and understand the consent forms, and to understand and complete the provided 
pain questionnaires.  To ensure the subjects’ understanding of the consent, they were 
asked questions to assess their understanding of what they were being asked to do, such 
as: 
 
1. Please describe in your own words the purpose of the study 
2. To make sure you understand what is expected of you, please expain what you 
are being asked to do in the study 
3. What more would you like to know? 
 
Exclusion Criteria 
Patients with documented allergies or intolerance to any of the proposed test 
medications or local anesthetic preparations, patients who were pregnant, patients who 
were currently on a pain medication for an unrelated condition, patients who had taken 
any pain medication within the last 4 hours, patients who were unwilling/unable to 
complete the pain scales for the first 48 hours following treatment, patients with a history 
of liver or kidney disease, and/or patients who were unable to understand and complete 
the consent form were excluded.  Participants also had the option to terminate their 
participation in the study at any time. 
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All endodontic treatment was performed by 8 graduate endodontic residents at the 
University of Minnesota School of Dentistry.  Prior to initiation of endodontic treatment 
each study participant was provided with a pre-packaged envelope which contained: 
 
1. 1 consent form (Appendix 1). 
2. 1 HIPAA Authorization to Use and Disclose form (Appendix 2). 
3. 1 Patient Information form to be completed by both the treatment provider and 
the patient (Appendix 3). 
4. 8 pain questionnaires (Appendix 4).  Each questionnaire included a 
Categorical scale, Visual Analog Scale (VAS), and a Heft Parker scale.  A 
questionnaire was to be filled out by the participant pre-operatively, 
immediately post-operatively, 1 hour following a first dose of a randomized 
pain medication, 1 hour following a second dose of the randomized pain 
medication, and at breakfast, lunch, dinner, and at bedtime the following day.  
The values of Categorical scales ranged from 0 (no pain) to 3 (severe pain).  
The VAS scales were 100 mm in length while the Heft Parker scales were 170 
mm in length.  Patients were requested to mark their perceived pain level on 
the provided scales and for the VAS and Heft Parker Scales, the marks were 
measured using a millimeter ruler to convert them to numerical scores. 
5. 2 paired local anesthetic cartridges, each containing either 1.7 mL 2% 
lidocaine with 1:100,000 epinephrine (Novocol Pharmaceutical, Cambridge, 
Ontario, Canada) or 1.8 mL 0.5% bupivacaine with 1:200,000 epinephrine 
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(Novocol Pharmaceutical, Cambridge, Ontario, Canada) to be used to achieve 
anesthesia prior to treatment.  The local anesthetic type included with each 
patient envelope was randomized, recorded, and cartridge labels were 
concealed with opaque masking tape during prior envelope assembly so that 
neither the treatment provider nor the patient were aware of the local 
anesthetic type to be administered.  The identity of the local anesthetic used in 
each treatment was not disclosed to the principal investigators until the end of 
the study.  Randomization was performed for anesthetic type rather than for 
each individual cartridge, such that both cartridges included in the envelope 
would be of the same type (e.g. lidocaine plus lidocaine or bupivacaine plus 
bupivacaine). 
6. Detailed written instructions outlining how and when to complete the 
questionnaires, medication time intervals, and protocols in the event of an 
emergency. 
7. Contact information for the principle investigators and a second entity outside 
of the School of Dentistry, should questions arise regarding the study. 
8. A pre-stamped, self-addressed envelope with which the patient was given the 
option to either return the questionnaires by mail or to deliver the forms in 
person at their next visit. 
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Thirty-one eligible patients signed the consent form, which outlined the 
procedures and possible risks associated with the study.  Prior to initiation of endodontic 
treatment, the following demographic data was recorded: 
 
1. Contact information 
2. Gender 
3. Age 
4. Tooth number to be treated 
5. Pre-operative pulpal and apical diagnosis based on the definitions in the 
American Association of Endodontists Glossary of Terms, 2012 
6. Specific procedure(s) to be completed 
 
The first pain questionnaire was completed by each participant before 
administration of local anesthetic in order to establish pre-treatment pain levels.  The 
entire volume of each of the two blinded local anesthetic cartridges were administered, 
and adequate time was given for the anesthetic to take effect.  Sufficient anesthesia for 
treatment was suspected when the patient experienced resolution of their pre-treatment 
symptoms, and in cases of irreversible pulpitis, when a #2 cotton pellet saturated with 
tetrofluoroethane refrigerant spray (Endo Ice, Coltene-Whaledent, Cuyahoga Falls, OH) 
placed against the tooth surface produced no response.  In cases where anesthesia was 
determined to be inadequate after administration of the two blinded cartridges included 
with the patient envelope, up to 1.7 mL of 2% lidocaine with 1:100,000 epinephrine was 
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administered as a supplement, however, this was rarely necessary.  No patients required 
more than 1 additional cartridge of supplemental anesthetic, and sufficient local 
anesthesia was obtained in all participants prior to initiation of treatment.  The volume of 
any supplemental anesthesia administered was recorded for consideration when analyzing 
the data.  The tooth to be treated was isolated with a rubber dam.  Endodontic access was 
performed, followed by identification and instrumentation of all canals, including 
removal of existing obturation materials in cases of previous endodontic treatment.  The 
minimum canal preparation size that was considered acceptable for inclusion in this study 
was to a #25 file or, in cases of previous endodontic treatment, to a minimum of size #35 
with removal of existing obturation materials.  Canals were instrumented to within 0.5 to 
1.0 mm of the apex, as determined by the combination of an electronic apex locator (Root 
ZX II, J. Morita USA, Irvine, CA) and digital periapical radiographs (Carestream Dental, 
Atlanta, GA).  Nickel-titanium rotary files (K3XF, SybronEndo, Orange, CA; Vortex 
Blue, Dentsply, York, PA; or ProTaper, Dentsply, York, PA) were used to enlarge canals, 
with a 5.25% sodium hypochlorite irrigation solution used between files.  Canals were 
dried using sterile paper points and calcium hydroxide intracanal medicament (Ultracal, 
Ultradent Products Inc, South Jordan, UT) was placed into canals using a syringe.  A 
sterile cotton pellet was placed in the pulp chamber, and a Cavit (3M, St. Paul, MN) 
temporary restoration was used to seal the endodontic access.   
For the purpose of standardization, all endodontic treatments performed in this 
study were carried out in two stages (a subsequent visit was required to complete the 
treatment), and only data related to the first stage of treatment was considered. 
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Following completion of the first-stage endodontic treatment, the participant was 
asked to complete the second pain questionnaire to establish immediate post-operative 
pain levels. 
A prescription written for the IRB study number was presented to an independent 
pharmacy (IDS Pharmacy; University of Minnesota), which was then filled according to 
a randomized reference code known only to the IDS pharmacy.  The prescription was 
provided in a sealed paper bag containing two vials marked ‘Dose #1’ and ‘Dose #2,’ 
with dose #1 to be taken one hour post-operatively (when the patient returns home) and 
dose #2 to be taken four hours following the first dose.  Within the medication vials were 
one of the following randomly assigned drug regimens: 
 
1. Dose #1 - Anaprox DS 550 mg (naproxen sodium), Dose #2 – Placebo 
2. Dose #1 – Placebo, Dose #2 – Placebo 
3. Dose #1 – Ibuprofen 800 mg, Dose #2 – Ibuprofen 800 mg 
4. Dose #1 – Ibuprofen 800 mg + hydrocodone 5 mg/acetaminophen 325 mg, 
Dose #2 Ibuprofen 800 mg + hydrocodone 5 mg/acetaminophen 325 mg 
 
The appropriate randomized drugs were provided in a generic form so that neither 
the patient nor the treatment provider were aware of the identity of the medication.  The 
IDS pharmacy provided a 24-hour phone service number in case of an emergency 
situation where the drug code could be un-blinded for the treatment provider/patient.  
Otherwise, the identity of the drugs associated with the reference code were not disclosed 
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to the principal investigators until the end of the study.  In the present study, no situation 
requiring un-blinding of the drug or inter-appointment emergency treatment occurred. 
Participants were instructed to take dose #1 of the assigned medication 
approximately one hour post-operatively (after returning home).  One hour after taking 
dose #1, participants completed the third pain questionnaire.  Dose #2 of the assigned 
medication was to be taken four hours following the first dose.  One hour after taking 
dose #2, participants completed the fourth pain questionnaire.  The remaining four 
questionnaires were completed at breakfast, lunch, dinner, and bedtime the following 
day.  In the event of any complications with the test medications, or in the event of any 
adverse symptoms/side effects, patients were encouraged to call the principle 
investigators.  Patients who elected to take additional pain medication or pain 
medications other those provided in the study were to indicate this on the questionnaires 
and were excluded from the study.  Upon completion of the questionnaires, patients were 
to return the forms in person at the subsequent visit, or by mail using the pre-stamped, 
self addressed envelope. 
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RESULTS 
 
A total of thirty-one patients were enrolled in this clinical trial from February 
2014 through April 2015.  Ten patients were unable to complete the study because they 
could not be reached following the 48-hour trial period and/or because they failed to 
return the pain questionnaires.  No patients were excluded due to the inability to achieve 
sufficient local anesthesia under the previously described research model.  Furthermore, 
no patients were excluded based on the need for emergency inter-appointment treatment 
or the use of additional pain medications within the 48-hour trial period.  Therefore, data 
from twenty-one patients was available for analysis. 
First, comparability between the two local anesthetic groups was evaluated 
according to baseline characteristics.  Table I compares the distribution of gender, age, 
and pre-operative pain as recorded on the Categorical scale, the VAS, and the Heft Parker 
scale (HP). 
 
Table I. Patient Baseline Characteristics 
 
Group	   n	   Gender	  
(f:m)	  
Mean	  
Age	  
(years)	  
Mean	  Initial	  
Categorical	  
Scale	  
Mean	  
Initial	  VAS	  	  
Mean	  
Initial	  HP	  	  
Lidocaine	   11	   7:4	   35.0	   2	   53.0	   94.2	  
Bupivacaine	   10	   4:6	   41.1	   2.4	   57.9	   102.7	  
 
 
Comparability between the two anesthetic groups was evaluated based on the 
distribution of vital (irreversible pulpitis) vs. non-vital (necrotic, previous treated, 
previously initiated) pre-operative pulpal status (Table II), apical diagnosis (Table III), 
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and arch (maxilla vs. mandible; Table IV).  The distribution of these characteristics 
between the two groups was similar. 
 
Table II. Vital vs. Non-vital Pulpal Status by Study Group 
 
Group Vital Non-vital n 
Lidocaine 5 6 11 
Bupivacaine 4 6 10 
 
 
Table III. Apical Diagnosis by Study Group 
 
Group	   SAP	   AAP	   AAA	   CAA	   Normal	   n	  
Lidocaine	   9	   1	   1	   0	   0	   11	  
Bupivacaine	   8	   0	   2	   0	   0	   10	  
 
SAP = symptomatic apical periodontitis; AAP = asymptomatic apical periodontitis;  
AAA = acute apical abscess; CAA = chronic apical abscess 
 
 
Table IV. Maxillary Teeth vs. Mandibular Teeth by Study Group 
 
Group Maxillary Mandibular n 
Lidocaine 9 2 11 
Bupivacaine 7 3 10 
 
 
Next, the effect of the local anesthetic solutions on pain measurements at the 
various time points was evaluated.  The anesthetic-group main effect examines whether 
the local anesthetic groups differ according to each patient’s average pain measurement 
over the seven post-operative time points (Table V).  The two groups showed similar 
trends. 
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Table V. Anesthetic-Group Main Effect 
 
Group	   Average	  CS	  (SEM)	   Average	  VAS	  (SEM)	   Average	  HP	  (SEM)	  
Lidocaine	   0.8	  (0.1)	   15.7	  (2.0)	   34.9	  (3.3)	  
Bupivacaine	   0.9	  (0.1)	   16.7	  (2.6)	   33.8	  (4.0)	  
 
 
The time main effect examines whether the average pain measurements differ at 
the seven post-operative time points (Table VI).  Pain measurements shows an overall 
trend where pain increases from the immediate post-operative period until mid-day on 
day 2, when a decreasing trend in pain measurements is observed.  
 
Table VI. Time Main Effect 
 
Time	   Average	  CS	  (SEM)	   Average	  VAS	  (SEM)	   Average	  HP	  (SEM)	  
Immediate	  post-­‐op	   0.7	  (0.2)	   11.2	  (3.5)	   26.8	  (5.5)	  
1	  hr	  following	  med	  #1	   1.0	  (0.1)	   18.8	  (3.6)	   38.8	  (5.3)	  
1	  hr	  following	  med	  #2	   0.9	  (0.2)	   16.0	  (4.2)	   33.6	  (6.5)	  
Day	  2	  breakfast	   1.0	  (0.2)	   19.0	  (4.8)	   41.5	  (7.6)	  
Day	  2	  lunch	   0.9	  (0.2)	   19.1	  (5.2)	   39.6	  (8.4)	  
Day	  2	  dinner	   0.9	  (0.2)	   16.9	  (4.7)	   36.7	  (7.4)	  
Day	  2	  bedtime	   0.6	  (0.2)	   12.1	  (4.0)	   24.0	  (6.6)	  
 
 
The group-by-time interaction examines whether the pain measurements between 
the two local anesthetic groups differ over time (Table VII).  A trend in which the 
bupivacaine group reports lower pain levels when compared to the lidocaine group is 
observed on the first day, followed by a comparatively higher pain level on day 2.  Both 
local anesthetic groups show a decreasing pain trend near the end of the second day. 
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Table VII. Group-by-Time Interaction 
 
Time Lidocaine Avg. 
VAS (SEM) 
Bupivacaine Avg. 
VAS (SEM) 
Immediate post-op 9.0 (3.4) 13.7 (6.6) 
1 hr following med #1 23.6 (6.0) 13.6 (3.3) 
1 hr following med #2 24.5 (6.9) 6.6 (1.9) 
Day 2 breakfast 15.8 (5.3) 22.5 (8.5) 
Day 2 lunch 16.0 (5.7) 22.7 (9.1) 
Day 2 dinner 12.0 (3.2) 22.3 (9.2) 
Day 2 bedtime 9.0 (4.5) 15.6 (7.0) 
 
 
When the group-by-time interaction is examined by pain measurements as 
reported on the Categorical scale (Fig. 2), VAS scale (Fig. 3), and Heft Parker scale (Fig. 
4), a similar trend for each of the two local anesthetic groups is observed. 
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Figure 2. Group-by-Time Interaction – Average Categorical scale reading at each 
time point.   
n = 10-11/group  Error Bars = S.E.M. 
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Figure 3. Group-by-Time Interaction – Average VAS reading at each time point 
n = 10-11/group  Error Bars = S.E.M. 
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Figure 4. Group-by-Time Interaction – Average Heft Parker scale reading at each 
time point 
n = 10-11/group  Error Bars = S.E.M. 
 
 
Next, we evaluated whether the post-operative pain levels in each treatment group 
differed when examined by patient sex (Fig. 5).  Interestingly, females who received 
bupivacaine reported higher levels of pain on day 2 when compared with males who 
received bupivacaine and females who received lidocaine.  Conversely, males who 
received lidocaine reported higher levels of pain when compared with females who 
received lidocaine and males who received bupivacaine. 
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Figure 5. Group-by-Time Interaction for Male vs. Female Patients – Average Heft 
Parker scale reading at each time point 
n = 4-7/group  Error Bars = S.E.M. 
 
 
Finally, the pain measurements were evaluated in a group-by-time interaction 
with respect to vital (irreversible pulpitis) or non-vital (necrotic, previously initiated 
treatment, previous treatment) pre-operative pulpal status (Fig. 6).  Patients with non-vital 
pulpal status reported slightly higher pre-operative pain levels, and a reduction in 
immediate post-operative pain levels occurred in both groups regardless of pre-operative 
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pulpal status.  A trend was observed in which patients with non-vital pulps receiving 
bupivacaine demonstrated higher levels of pain on day 2.   
 
Figure 6. Group-by-Time Interaction for Vital vs. Non-Vital Pulp – Average VAS 
reading at each time point 
n = 4-6/group  Error Bars = S.E.M. 
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DISCUSSION 
The ability to deliver endodontic treatment is impossible without the use of 
effective local anesthesia.  Although the focus of endodontic treatment is the removal and 
reduction of bacterial and immunologic factors from the root canal system (Hargreaves et 
al. 1994; Keiser and Byrne 2011), many patients report some level of post-operative pain 
following treatment (O'Keefe 1976; Harrison et al. 1983; Georgopoulou et al. 1986), and 
that post-operative pain is most severe within the first 24 hours following treatment 
(Harrison et al. 1983; Torabinejad et al. 1994b; Mattscheck et al. 2001).  For these 
reasons, a flexible analgesic prescription plan has been recommended (Troullos et al. 
1986; Keiser and Hargreaves 2002; Hargreaves and Keiser 2004).  In addition to the 
analgesic benefits that can be achieved with drugs such as NSAIDs and opioids, it has 
been demonstrated that long-acting local anesthetics can provide analgesia that lasts well 
beyond the initial period of anesthesia (Moore and Dunsky 1983; Dunsky and Moore 
1984; Crout et al. 1990; Keiser and Hargreaves 2002). 
In this clinical trial, data from 21 patients was available for evaluation.  Patients 
were administered either an intermediate-acting local anesthetic (2% lidocaine with 
1:100,000 epinephrine), or a long-acting local anesthetic (0.5% bupivacaine with 
1:200,000 epinephrine) prior to initiation of emergency endodontic treatment.  A 
randomized drug regimen consisting of either an NSAID (naproxen sodium or 
ibuprofen), a combination anti-inflammatory/analgesic (ibuprofen + 
hydrocodone/acetaminophen), or placebo was provided to simulate a modern clinical 
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endodontic situation.  Lidocaine served as positive control, while bupivacaine was 
included to investigate its potential analgesic effects. 
Although the number of patients included in this clinical trial was too few to 
perform meaningful statistical analysis, several trends were suggested.  First, the group-
by-time interaction evaluated whether the pain levels reported between the two local 
anesthetic groups changed over time.  For both the lidocaine and bupivacaine groups, a 
notable reduction in immediate post-operative pain was observed.  Patients in the 
lidocaine group reported pain levels that increased in time periods following the 
immediate post-operative period during the first day, while pain levels for the 
bupivacaine group remained relatively lower during the same period.  
The trends observed in this study for the first three post-operative measurement 
periods are in agreement with previous studies conducted using similar endodontic 
models, where post-operative pain levels reported by patients receiving bupivacaine were 
significantly lower in the first 12 hours when compared with patients who received 
lidocaine (Moore and Dunsky 1983; Parirokh et al. 2012; Al-Kahtani 2014). 
However, in the present study, these trends reversed on day 2 (12+ hours), where 
the bupivacaine group demonstrated increased pain levels while the lidocaine group 
reported lower levels of pain.  These results are in conflict with the results of the 
aforementioned studies.  Moore and Dunsky observed significantly reduced pain levels 
over a 24-hour post-operative period for patients who received bupivacaine (Moore and 
Dunsky 1983).  Parirokh et al. and Al-Kahtani observed lower pain levels beyond the first 
12-hour period in patients who received bupivacaine, but the differences were not found 
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to be significant (Parirokh et al. 2012; Al-Kahtani 2014). Several differences in the study 
models, in combination with the low number of subjects in the present study may account 
for these conflicting results.  In the present study, only patients with a current level of 
spontaneous pain were included (patients that required application of a stimulus to 
reproduce their symptoms were excluded).  Moore and Dunsky did not evaluate pre-
operative pain levels, and pre-operative symptoms were not required for inclusion 
(Moore and Dunsky 1983).  Studies by Parirokh et al. and Al-Kahtani included only 
patients with irreversible pulpitis and absence of percussion symptoms, and Parirokh et 
al. excluded patients with spontaneous pain.  Furthermore, the present study model 
consisted only of the first-stage of two-visit endodontic treatment (pulpal debridement 
followed by calcium hydroxide interappointment medication). Moore and Dunsky’s study 
model included single-visit treatment, two-visit treatment, and endodontic surgery. 
Parirokh et al. and Al-Kahtani performed only single-visit treatment consisting of 
obturation with gutta-percha and AH-plus sealer, which may have had differing effects 
on apical tissues from one patient to the next.  Finally, a potential problem with the 
current study was the large proportion of maxillary teeth treated compared to mandibular 
teeth; Infiltration-type anesthesia rather than nerve block was likely achieved in many of 
the patients, which may have had a negative affect on the overall duration of 
anesthesia/analgesia.  Parirokh et al. and Al-Kahtani included only mandibular molars 
anesthetized by administration of inferior alveolar nerve block. 
Both local anesthetic groups in the present study showed a decreasing pain trend 
near the end of the second day, which lends further support to previous evidence that 
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endodontic post-operative pain is most severe within the first 24 hours following 
treatment, yet moderately decreased from pre-operative pain levels the patient presented 
with. 
Examination of the group-by-time interaction with respect to sex differences 
suggested interesting trends.  Females in the bupivacaine group reported notably higher 
pain levels on the second day when compared with females in the lidocaine group and 
males in bupivacaine group.  Conversely, males in the lidocaine group reported notably 
higher pain levels when compared with males in the bupivacaine group and females in 
the lidocaine group.  These trends suggest the possibility that bupivacaine may be more 
effective at providing prolonged analgesia in males, however the population in the 
present study is too small to draw such a conclusion and further research is needed.  
Furthermore, the impact of the various analgesic regimens administered cannot be ruled 
out due to the unfortunately small number of subjects included in this study.  
Nevertheless, the trends observed in the present study for the two local anesthetic groups 
with respect to sex differences might be explained by the findings of Morin et al. (2000) 
where females experienced more intense post-surgical pain than males, but males were 
found to be more disturbed than women by low levels of pain over several days.  
Therefore, from the present study, the hypothesis could be made that males experienced 
less adequate analgesia than males in the bupivacaine group resulting pain of greater 
duration and increased perception of pain. 
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CONCLUSIONS 
 
From the trends observed in this study, it can be suggested that: 
1. The use of a long-acting local anesthetic (0.5% bupivacaine with 1:200,000 
epinephrine) may provide extended analgesia in the first day following 
emergency endodontic treatment when compared to an intermediate-acting 
local anesthetic (2% lidocaine with 1:100,000 epinephrine). 
2. The use of a long-acting versus an intermediate-acting local anesthetic may 
not result in lower post-operative pain levels at later time periods (during the 
second day following treatment).  
3. Males may benefit more than females from the extended analgesic effects of 
long-acting local anesthetics. 
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APPENDIX 1 
 
CONSENT FORM 
Local Anesthesia and Analgesics in Post-Operative Endodontic Pain 
 
You are invited to participate in a research study of the effect of different pain 
medications and local anesthetics for tooth pain after beginning a root canal.   You were 
selected as a possible participant because you have tooth pain and are in need of root 
canal treatment for your tooth. We ask that you read this form and ask any questions you 
may have before agreeing to be in the study. 
 
This study is being conducted by Walter Bowles DDS PhD, Steven Wiswall DDS, and 
Riley Lewis DDS, Division of Endodontics at the University of Minnesota School of 
Dentistry.  It is funded by the Endodontics division, to examine methods for pain relief 
after starting a root canal. 
 
Study Purpose 
 
The purpose of the study is to determine the best way to treat tooth pain after starting a 
root canal, by evaluating your pain level before treatment and after treatment when you 
are given local anesthetic and pain medication.  We will provide regular or long-lasting 
local anesthesia before starting the root canal, and pain medication after the root canal to 
determine which method(s) provide the best pain relief.  
 
Study Procedures 
 
If you agree to participate in this study, we would ask you to do the following: Evaluate 
the amount of tooth pain you are having (mark on pain scales the level of pain you feel) 
before and after root canal treatment, after taking pain medication, and during the 
following day.  You will be given either local anesthetic or long-acting local anesthetic 
before the root canal, and you will be given two doses of pain medication to take during 
the first day.  After evaluating your tooth pain level at several time points each day till the 
end of the day following the root canal, you will then need to mail the forms back to the 
University in a pre-addressed, postage paid envelope.   
 
The root canal procedure is the standard treatment for this type of tooth pain and the 
medications given are standard pain medication given to patients reporting tooth pain.  
Assignment to study groups is randomized and all patients will get anesthetic (local or 
long acting local anesthetic), take 2 doses of pain medication and fill out pain level 
forms.   
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Risks of Study Participation 
 
The study has the following risks:  analgesic medication may have a side effect of 
stomach upset or may cause drowsiness. 
 
Benefits of Study Participation 
 
There is no direct benefit to the patients enrolled. 
 
Alternatives to Study Participation 
 
If you do not wish to participate, you may proceed with local anesthetic and root canal 
treatment. 
 
Study Costs/Compensation 
 
You will not incur any costs due to research participation.  The root canal procedure will 
be charged in the regular manner.  The emergency treatment fee (approximately $175) 
will not be charged if you decide to participate in the study for your time and 
inconvenience or, if this fee is covered by other monies, this amount may be credited 
toward the endodontic treatment fee if you so wish.  The emergency fee reduction is pro-
rated for partial participation (i.e. if not all pain evaluation forms returned) and will be 
reduced to approximately half ($85 credit) if only first 2 pain forms are filled out, and 
$15 credit for each of the pain scales filled out at home and returned (6 other forms given 
in take home packet $90 credit) 
 
Research Related Injury 
 
In the event that this research activity results in an injury, treatment will be available, 
including first aid, emergency treatment and follow-up care as needed. Care for such 
injuries will be billed in the ordinary manner to you or your insurance company. If you 
think that you have suffered a research related injury, let the study dentists know right 
away. 
 
Confidentiality 
 
The records of this study will be kept private. In any publications or presentations, we 
will not include any information that will make it possible to identify you as a subject. 
Your record for the study may, however, be reviewed by departments at the University 
with appropriate regulatory oversight. Study information will be recorded in the your 
medical record stating only the study number and that you were given pain medication.   
To these extents, confidentiality is not absolute. Study data will be encrypted according 
to current University policy for protection of confidentiality.  
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A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as 
required by U.S. law.  This Web site will not include information that could identify you. 
At most, the Web site will include a summary of the results. You can search this Web site 
at any time. 
 
Protected Health Information (PHI) 
 
Your PHI created or received for the purposes of this study is protected under the federal 
regulation known as HIPAA.  Refer to the attached HIPAA authorization for details 
concerning the use of this information.  
 
Voluntary Nature of the Study 
 
Participation in this study is voluntary. Your decision whether or not to participate in this 
study will not affect your current or future relations with the University. If you decide to 
participate, you are free to withdraw at any time without affecting those relationships.   
 
Contacts and Questions 
 
The researchers conducting this study are Walter Bowles DDS PhD, Steven Wiswall 
DMD, and Riley Lewis DDS.  You may ask any questions you have now, or if you have 
questions later, you are encouraged to contact them at 612-624-9900 (Division of 
Endodontics, University of Minnesota School of Dentistry)  
 
If you have any questions or concerns regarding the study and would like to talk to 
someone other than the researcher(s), you are encouraged to contact the Fairview 
Research Helpline at telephone number 612-672-7692 or toll free at 866-508-6961.  You 
may also contact this office in writing or in person at Fairview Research Administration, 
2344 Energy Park Drive, St. Paul, MN  55108. 
 
You will be given a copy of this form to keep for your records. 
 
Statement of Consent 
 
I have read the above information.  I have asked questions and have received answers.  I 
consent to participate in the study.  
 
Signature of Subject______________________________ Date_________________ 
 
 
 
Signature of Person Obtaining Consent_______________ Date_________________ 
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APPENDIX 2 
 
HIPAA1 AUTHORIZATION TO USE AND DISCLOSE 
INDIVIDUAL HEALTH INFORMATION FOR RESEARCH PURPOSES 
 
 
 
1.  Purpose.  As a research participant, I authorize [name of PI] and the researcher’s staff 
to use and disclose my individual health information for the purpose of conducting the 
research project entitled [title of study], Human Subjects Code #1311M45821. 
 
2.  Individual Health Information to be Used or Disclosed.  My individual health 
information that may be used or disclosed to conduct this research includes: [List all of 
the individual health information to be collected for this protocol/study such as 
demographic information, results of physical exams, blood tests, x-rays, and other 
diagnostic and medical procedures as well as medical history]. 
 
3.  Parties Who May Disclose My Individual Health Information.  The researcher and 
the researcher’s staff may obtain my individual health information from: 
 
Hospitals:  
Clinics:  
Other 
Providers:  
Health Plan:  
 
and from hospitals, clinics, health care providers and health plans that provide my 
health care during the study. 
 
4.  Parties Who May Receive or Use My Individual Health Information.  The 
individual health information disclosed by parties listed in item 3 and information 
disclosed by me during the course of the research may be received and used by Walter 
Bowles DDS PhD and the researcher’s staff  Also, if I receive compensation for 
participating in this study, identifying information about me may be used or disclosed as 
necessary to provide compensation. 
 
                                                
1 HIPAA is the Health Insurance Portability and Accountability Act of 1996, a federal law related to privacy of health 
information. 
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5.  Right to Refuse to Sign this Authorization.  I do not have to sign this Authorization.  
If I decide not to sign the Authorization, I may not be allowed to participate in this study 
or receive any research related treatment that is provided through the study.  However, 
my decision not to sign this authorization will not affect any other treatment, payment, or 
enrollment in health plans or eligibility for benefits.  
 
6.  Right to Revoke.  I can change my mind and withdraw this authorization at any time 
by sending a written notice to [researcher’s name and address]  to inform the researcher 
of my decision.  If I withdraw this authorization, the researcher may only use and 
disclose the protected health information already collected for this research study.  No 
further health information about me will be collected by or disclosed to the researcher for 
this study. 
 
7.  Potential for Re-disclosure.  Once my health information is disclosed under this 
authorization, there is a potential that it will be re-disclosed outside this study and no 
longer covered by this authorization. However, the research team and the University’s 
Institutional Review Board (the committee that reviews studies to be sure that the rights 
and safety of study participants are protected) are very careful to protect your privacy and 
limit the disclosure of identifying information about you. 
 
7A. Also, there are other laws that may require my individual health information to be 
disclosed for public purposes.  Examples include potential disclosures if required for 
mandated reporting of abuse or neglect, judicial proceedings, health oversight 
activities and public health measures. 
 
[researcher’s name and address]  
  
This authorization does not have an expiration date. 
 
I am the research participant or personal representative authorized to act on behalf of the 
participant. 
 
I have read this information, and I will receive a copy of this authorization form after it is 
signed. 
 
 
_______________________________ ___________________________________ 
signature of research participant or research participant’s                 date 
personal representative 
 
_______________________________ ___________________________________ 
printed name of research participant or research participant’s  description of personal representative’s authority to act on behalf 
personal representative              of the research participant 
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APPENDIX 3 
 
PATIENT INFORMATION 
FOR INVESTIGATIONAL DRUG STUDIES PHARMACY 
 
The Investigational Drug Studies Pharmacy needs the following information on all study patients. 
 
PATIENT’S FULL NAME: (first,middle,last)______________________________________________ 
 
PATIENT’S ADDRESS: 
 
! STREET: ___________________________________________________________ 
 
! CITY & STATE: ______________________________________________________ 
 
! ZIP CODE: __________________________________________________________ 
 
! TELEPHONE NUMBER: _______________________________________________ 
 
 
PATIENT’S SEX: ________ MALE  ________ FEMALE 
 
PATIENT’S DATE OF BIRTH (MM/DD/YYYY): __ __/ __ __/ __ __ __ __ 
 
PATIENT’S HOSPITAL NUMBER (if one has been assigned): ____________________________ 
 
ALLERGIES TO MEDICATIONS:  
 
 
 
 
 
 
 
PRIOR ADVERSE REACTIONS TO DRUGS: ________ NONE  ________ YES 
IF YES –  LIST DRUG AND TYPE OF REACTION EXPERIENCED (i.e. nausea, hives, 
difficulty breathing, etc.)  WE MUST BE GIVEN PRIOR ADVERSE 
REACTIONS TO DRUG INFORMATION 
 
 
 
 
 
 
 
 
Study Name/IDS #: ___________________________________________________ 
 
Study Coordinator/Contact Person: _________________________________________________ 
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 Phone Number: ________________ 
 
Fax the completed form to the Investigational Drug Studies Pharmacy: 612-273-2176.  IDS Pharmacy must 
have a completed form before any prescriptions can be dispensed. 
 
Please call the Pharmacy, at 612-273-6212, with any questions.                   Thank You. 
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APPENDIX 4 
(not to scale) 
Laboratory of Neuropharmacology
School of Dentistry
515 Delaware Street SE
Mpls, MN 55455
UNIVERSITY OF MINNESOTA
STUDY: 
PATIENT #______
DATE:__________
Check the box that best describes the amount of pain that you feel now:
3 = Severe
2 = Moderate
1 = Mild
0 = None
Place a mark on the line to show the amount of PAIN  that you feel now:
 No
Pain
Pain As Much As
    It Could Be
Place a mark on the line to show the amount of PAIN  that you feel now:
None Faint Weak Mild Moderate Strong Intense Maximum
Possible
CLOCK TIME:__________
Have you taken any medication since the last report?   yes /no
Have you experienced any adverse effects or benefits from this medication?  
yes /no 
If yes, please describe.
TIME POINT:
 
IDS #4497
Pre-op (form #1) 
Form #1
 
 
 
